e-CBT for Bipolar Disorder
Trial Summary
What is the purpose of this trial?
The lifetime prevalence of Bipolar II is 0.4% with the time spent with depressive symptoms outnumbering the time spent with hypomanic symptoms by 35 to 1. Regarding current treatment options, psychotherapy is effective for managing depressive symptoms, with CBT being particularly efficacious. Unfortunately, CBT is often not a feasible treatment option. Electronic CBT (e-CBT) is more accessible for treating various mental illnesses with evidence suggesting it can increase treatment adherence and patient satisfaction. Moreover, e-CBT is suggested to have comparable outcomes to in-person CBT in the treatment of depression and anxiety. Typically, patient-clinician interactions of e-CBT are administered through email however, this is an insecure, unsustainable, and non-scalable treatment delivery method. The proposed study will use the Online Psychotherapy Tool (OPTT), a secure cloud-based platform for the delivery of e-CBT. The aim is to evaluate the feasibility and effectiveness of using OPTT for the treatment of BAD-II with depressive symptoms, while also analyzing social, cultural, and personal factors affecting patients' experience. Participants (n = 80) diagnosed with BAD-II in a depressive episode will be recruited from the Mood and Anxiety Clinic at Providence Care Hospital in Kingston, Ontario, Canada. Eligible participants will then be randomly assigned to either the treatment group (e-CBT plus treatment as usual (TAU)) (n = 40) or the control group (TAU) (n = 40) where they will complete the 12-week program. Participants in the TAU group will be offered the e-CBT program after the first 12 weeks if they wish to take part. Participants in the e-CBT group will complete weekly modules mirroring in-person CBT content and complete homework assignments that will be evaluated by a clinician who will provide personalized feedback through OPTT. Progression/regression of participants will be analyzed using the MADRS, YMRS, and CGI-BP-M questionnaires administered at baseline, after week 6, and after week 12. Personal, social, and cultural factors impacting participant experience will be investigated through an in-depth interview utilizing focus groups. The findings from this study will be the first on the effectiveness of delivering e-CBT to patients with BAD-II with residual depressive symptoms. This approach can provide an innovative method to address the barriers associated with in-person psychotherapy.
Do I need to stop my current medications to join the trial?
The trial does not specify whether you need to stop taking your current medications. It seems likely that you can continue your usual treatment, as the study involves adding e-CBT to your existing care.
What data supports the effectiveness of the treatment e-CBT for Bipolar Disorder?
Research shows that internet-delivered cognitive behavioral therapy (iCBT) can significantly reduce symptoms of anxiety and depression in people with bipolar disorder, with large improvements reported in psychological distress and patient satisfaction. This suggests that e-CBT could be a promising treatment option for managing bipolar disorder.12345
How is e-CBT different from other treatments for bipolar disorder?
e-CBT (Electronic Cognitive Behavioral Therapy) is unique because it is delivered online, allowing patients to access therapy from home, which can increase accessibility and convenience. It focuses on helping patients identify and change unhelpful thoughts and behaviors, and has shown effectiveness in reducing symptoms of depression and anxiety in people with bipolar disorder, especially when used alongside medication like Lithium.56789
Research Team
Nazanin Alavi
Principal Investigator
Kingston Health Sciences Centre
Eligibility Criteria
This trial is for individuals with Bipolar Disorder II (BAD-II) currently experiencing depressive symptoms. They must have reliable internet access, understand and speak English, and be able to consent to participate. People are excluded if they've had CBT in the last year, show active suicidal or homicidal thoughts, are in a hypomanic/manic phase, have acute psychosis or severe substance abuse issues.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive e-CBT through OPTT for 12 weeks, completing weekly modules and homework assignments
Follow-up
Participants are monitored for safety and effectiveness after treatment using MADRS, YMRS, and CGI-BP-M questionnaires
Open-label extension (optional)
Participants in the control group are offered the e-CBT program after the first 12 weeks
Treatment Details
Interventions
- e-CBT (Behavioral Intervention)
e-CBT is already approved in Canada for the following indications:
- Depression
- Anxiety disorders
- Phobias
- PTSD
- Sleep disorders
- Eating disorders
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dr. Nazanin Alavi
Lead Sponsor
Dr. Nazanin Alavi
Lead Sponsor
Queen's University
Lead Sponsor
Marie Evangelista
Queen's University
Chief Executive Officer
PhD in Cell and Molecular Biology from Queen's University, Ontario, Canada
Constantine Kreatsoulas
Queen's University
Chief Medical Officer since 2021
PhD in Chemistry from Princeton University
Online PsychoTherapy Clinic
Collaborator